Oral treatment with donepezil
Preclinical
Oral treatment with donepezil is one of 36 therapeutic programs targeting Alzheimer's Disease. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
54 competitors in Alzheimer's Disease
#DrugCompanyPhaseTrials
1Aricept
EisaiApproved
Leqembi
EisaiPhase 3
Nuplazid
AACADIA Pharmaceuticals Inc.
Approved
Ozempic
Novo NordiskPhase 3
Namenda
AbbViePhase 2
Briviact
UCBPhase 2
Leukine
SanofiPhase 2
Niacor
AbbViePhase 2
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Hytrin
AAbbott
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Alzheimer's Disease1 trial
A Multicenter Randomized Controlled Trial on the Efficacy and Safety of Cervical Lymph Vessel/Node-venous Anastomosis Combined With Donepezil Versus Donepezil Alone in the Treatment of Alzheimer's Disease
Not yet recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Preclinical·NCT07680660·216 enrolled
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]